Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | TACR2 | P21452 | 1/20 | 0.40 |
| ▸ | SENP5 | Q96HI0 | 1/20 | 0.40 |
| ▸ | SENP2 | Q9HC62 | 1/20 | 0.40 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23506368 | 1.00 | OPRM1 (0.41) | OPRM1CTSLSLC6A2SLC6A4TACR2 | |
| SCHEMBL23506382 | 1.00 | OPRM1 (0.41) | OPRM1CTSLSLC6A2SLC6A4TACR2 | |
| SCHEMBL23711631 | 0.95 | CTSL (0.45) | OPRM1CTSLSLC6A2SLC6A4TACR2 | |
| SCHEMBL21702244 | 0.95 | CTSL (0.45) | OPRM1CTSLSLC6A2SLC6A4TACR2 | |
| SCHEMBL23506316 | 0.95 | CTSL (0.45) | OPRM1CTSLSLC6A2SLC6A4TACR2 | |
| SCHEMBL21702278 | 0.89 | KLKB1 (0.51) | CTSLTACR2 | |
| SCHEMBL23506293 | 0.89 | KLKB1 (0.51) | CTSLTACR2 | |
| SCHEMBL23506231 | 0.88 | OPRM1 (0.43) | OPRM1SLC6A2SLC6A4 | |
| SCHEMBL23506317 | 0.88 | OPRM1 (0.43) | OPRM1SLC6A2SLC6A4 | |
| SCHEMBL23506253 | 0.88 | OPRM1 (0.47) | OPRM1CTSLSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133600-A1 | PHARMACEUTICAL USE OF KETOAMIDE-BASED COMPOUND | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-05-04 | — | — | US | disclosed |
| WO-2021151387-A1 | PHARMACEUTICAL USE OF KETOAMIDE-BASED COMPOUND | 中国科学院上海药物研究所 | 2021-08-05 | — | — | WO | disclosed |
| WO-2020030143-A1 | KETOAMIDE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | 中国科学院上海药物研究所 | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133600-A1 | PHARMACEUTICAL USE OF KETOAMIDE-BASED COMPOUND | CTSL, CTSV, CTSS | OPRM1 1004/4885CTSL 1/4885SLC6A2 4182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.